Axonics Modulation Technologies said today it raised $38.5 million in a Series B financing round for its sacral neurmodulation technology. Irvine, Calif.-based Axonics is developing a miniaturized rechargeable neuromod stimulator to treat overactive bladder, urinary retention and fecal incontinence. Proceeds from the round will go towards a clinical study of its neurmod device in treating […]
Axonics Modulation Technologies said it raised nearly $17.3 million in an equity financing as it develops next-generation neuromodulation technology to treat various medical conditions.
The California company disclosed the funding in a recent regulatory filing that does not name specific investors.
Axonics Modulation Technologies said it drummed up a $32.6 million Series A round for the neuromodulation technology it’s developing to treat chronic pain and overactive bladder.
Irvine, Calif.-based Axonics said the round was led by Edmond de Rothschild Investment Partners and included NeoMed Management, Legend Capital and "a select group of private individuals."